Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary autoimmune myelofibrosis: A case report in a child.
Hexner-Erlichman Z, Yacobovich J, Trougouboff P, Avraham-Kelbert M, Eitam H, Spiegel R, Yeganeh S, Levin C. Hexner-Erlichman Z, et al. Among authors: yeganeh s. EJHaem. 2020 Jun 28;1(1):304-308. doi: 10.1002/jha2.38. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847714 Free PMC article.
Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Ganzel C, et al. Among authors: yeganeh s. Leuk Lymphoma. 2020 Sep;61(9):2221-2225. doi: 10.1080/10428194.2020.1761964. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32420775
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.
Ganzel C, Trestman S, Levi S, Gatt ME, Lavi N, Vaxman I, Rouvio O, Magen H, Lebel E, Horowitz NA, Leiba M, Tadmor T, Herzog Tzarfati K, Surio C, Yeganeh S, Dally N, Avivi I, Cohen YC. Ganzel C, et al. Among authors: yeganeh s. Leuk Lymphoma. 2022 Dec;63(14):3448-3455. doi: 10.1080/10428194.2022.2118535. Epub 2022 Sep 8. Leuk Lymphoma. 2022. PMID: 36075048
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
Levy I, Lavi A, Zimran E, Grisariu S, Aumann S, Itchaki G, Berger T, Raanani P, Harel R, Aviv A, Lavi N, Zuckerman T, Shvidel L, Jarchowsky O, Ellis M, Herzog Tzarfati K, Koren-Michowitz M, Sherf Y, Levi I, Sofer O, Shpilberg O, Dally N, Suriu C, Braester A, Ben Barouch S, Leiba M, Goldstein D, Sarid N, Yeganeh S, Halloun J, Mittelman M, Tadmor T. Levy I, et al. Among authors: yeganeh s. Leuk Lymphoma. 2021 Dec;62(14):3384-3393. doi: 10.1080/10428194.2021.1966782. Epub 2021 Aug 18. Leuk Lymphoma. 2021. PMID: 34405767
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y. Merkel D, et al. Among authors: yeganeh s. Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368. Am J Hematol. 2013. PMID: 23345248 Free article.
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.
Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM. Zuckerman T, et al. Among authors: yeganeh s. Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468. Blood Adv. 2019. PMID: 31770437 Free PMC article. Clinical Trial.
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D. Ofran Y, et al. Among authors: yeganeh s. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25819366
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Gatt ME, Hardan I, Chubar E, Suriu C, Tadmor T, Shevetz O, Patachenco P, Dally N, Yeganeh S, Ballan-Haj M, Cohen Y, Trestman S, Muchtar E, Magen H, Jakubinsky J, Avivi I; Israeli MM study group. Gatt ME, et al. Among authors: yeganeh s. Eur J Haematol. 2016 Feb;96(2):136-43. doi: 10.1111/ejh.12558. Epub 2015 Apr 17. Eur J Haematol. 2016. PMID: 25827161
63 results